Boehringer Ingelheim has announced the start of a Phase II trial for BI 3034701, a triple GLP-1/GIP/NPY2 receptor agonist, in adults with obesity or overweight. The development reflects the company's efforts to build a layered obesity portfolio rather than relying solely on survodutide, its dual glucagon/GLP-1 agonist now in Phase III.
The molecule simultaneously activates three receptors: GLP-1 and GIP receptors to reduce appetite and regulate metabolism, and the neuropeptide Y2 receptor, which modulates central hunger signaling. NPY2R agonism is the differentiating element — the receptor's role in broader eating behavior remains under investigation, which is precisely what the Phase II study is designed to begin addressing. BI 3034701 was developed in collaboration with Denmark-based Gubra; Boehringer holds sole responsibility for development and commercialization.
The Phase II study, registered as NCT07662122, is a dose-finding and efficacy evaluation in people with obesity or overweight. No enrollment figures or primary endpoints were disclosed, and no efficacy data exist. Phase I studies reported a generally favorable safety and tolerability profile, the threshold typically required to advance a peptide into mid-stage development.
Boehringer is engaged in portfolio construction with BI 3034701. Survodutide recently reported 16.6% mean body weight reduction at 76 weeks in the Phase III SYNCHRONIZE-1 trial, meeting both co-primary endpoints, while its glucagon receptor component is also being evaluated in MASH through the LIVERAGE program. BI 3034701 represents a next-generation asset intended to address patients who may not respond adequately to GLP-1–based mechanisms alone, or for whom the behavioral and central drivers of obesity require a different pharmacological approach.